| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HLA-B |
| Uniprot No | Q96DW9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-308aa |
| 氨基酸序列 | GSHSMRYFYTAMSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQICKTNTQTYRESLRNLRGYYNQSEAGSHTLQRMYGCDVGPDGRLLRGHDQYAYDGKDYIALNEDLSSWTAADTAAQITQRKWEAAREAEQLRAYLEGLCVEWLRRYLENGKETLQRADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTIPI |
| 预测分子量 | 36.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HLA-B重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Structural characterization of HLA-B*57:01-recombinant protein for HIV immune response analysis*
**作者**：Smith A, et al.
**摘要**：研究通过重组技术表达HLA-B*57:01蛋白，解析其晶体结构，揭示其与HIV抗原肽的结合特性，为HIV疫苗设计提供结构基础。
2. **文献名称**：*Recombinant HLA-B*27:05 production and its role in ankylosing spondylitis pathogenesis*
**作者**：Chen L, Wang Y.
**摘要**：利用哺乳动物细胞系统高效表达HLA-B*27:05重组蛋白，证明其异常折叠与内质网应激相关，可能参与强直性脊柱炎的自身免疫反应机制。
3. **文献名称**：*HLA-B*35:01 recombinant protein as a biomarker for carbamazepine-induced hypersensitivity*
**作者**：Nguyen T, et al.
**摘要**：开发重组HLA-B*35:01蛋白检测技术，验证其与卡马西平药物过敏反应的强相关性，为临床药物安全性预测提供新方法。
(注：以上文献为示例性内容，实际引用需查询具体数据库如PubMed或Web of Science。)
HLA-B recombinant protein is a genetically engineered version of the human leukocyte antigen B (HLA-B), a critical component of the major histocompatibility complex (MHC) class I molecules in humans. HLA-B plays a central role in adaptive immunity by presenting peptide antigens derived from intracellular pathogens or abnormal cellular proteins to CD8+ T cells, triggering targeted immune responses. Its extensive genetic polymorphism—over 4.000 documented alleles—contributes to population-level diversity in antigen presentation, influencing disease susceptibility, transplant compatibility, and drug hypersensitivity reactions.
Recombinant HLA-B proteins are typically produced using expression systems like *E. coli*, insect cells, or mammalian cells. These systems enable precise control over protein folding and post-translational modifications, crucial for maintaining structural integrity and functional peptide-binding grooves. The recombinant form retains the α-heavy chain non-covalently bound to β2-microglobulin, often stabilized with specific antigenic peptides for experimental consistency.
In research, HLA-B recombinant proteins are indispensable tools for studying immune recognition mechanisms, T cell receptor interactions, and autoimmune disease pathogenesis (e.g., HLA-B27-associated spondyloarthritis). They facilitate high-throughput epitope screening for vaccine development and cancer immunotherapy, where HLA-B-restricted neoantigens are targeted. Additionally, they aid in characterizing alloreactive immune responses in transplant rejection and HLA-associated drug toxicities (e.g., carbamazepine hypersensitivity linked to HLA-B*15:02). Their standardized production supports diagnostic assay development and personalized therapeutic strategies, bridging genetic variability with functional immunology studies.
×
